Further research needed to assess real-world implementation, population-based screening and initiation of prophylaxis
A regular, affordable penicillin treatment can prevent the risk of underlying rheumatic heart disease (RHD) progression in children and adolescents, according to a new study.
RHD is serious heart damage caused by rheumatic fever — a condition arising from poorly treated, repeat infections of streptococcus bacteria. Worldwide, around 40.5 million people, mostly people under the age of 25, suffer from the disease and 306,000 people die of it every year, according to recent estimates.
RHD remains a public health concern in low-resource countries like Uganda, where it is the most common cause of heart disease in young adults. Ugandan patients, moreover, present late in the disease course and almost half present with a complication.
In this study, the researchers conducted a randomised controlled trial of secondary antibiotic prophylaxis in Ugandan children and adolescents aged 5-17 years in primary and secondary schools in Gulu, Uganda from July 2018 through October 2020.
Among 102,200 children and adolescents, 926 received a definitive diagnosis of latent rheumatic heart disease on the basis of confirmatory echocardiography. They were randomly assigned to receive either injections of penicillin G benzathine every four weeks for two years or no treatment.
The study result showed secondary antibiotic prophylaxis reduced the risk of disease progression at two years. The findings were published in the New England Journal of Medicine November 13, 2021.
The study concluded that further research is needed to assess real-world implementation, population-based screening and initiation of prophylaxis. The research may be integral components of the National Rheumatic Heart Disease action plans envisioned by the World Health Assembly in 2017 to stop rheumatic heart disease.
This study is the first large-scale clinical trial to understand the scope of penicillin usage in RHD treatment. It was led by an international panel of pediatric cardiac experts from Children’s National, Cincinnati Children’s Medical Center, the Uganda Heart Institute and Murdoch Children’s Research Institute in Melbourne, Australia.
On May 25, 2018, member states of the World Health Organization (WHO) unanimously adopted a Global Resolution on Rheumatic Fever and Rheumatic Heart Disease at the World Health Assembly in Geneva, Switzerland.
This historic decision marks the first time that Rheumatic Fever and RHD have been recognised as global health priorities on the world stage.
The Uganda Heart Institute, a semi-autonomous, publicly-funded clinical and research facility in Kampala, has engaged with the Uganda Ministry of Health to develop a national RHD strategy in response to the World Health Assembly (WHA) Resoultion.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.